Innovation Pharmaceuticals Inc (IPIX)

[DesireToLearn]

From a late May PR....Additional preliminary data analyses of secondary endpoints show patients who received any dose of Prurisol, regardless of the treatment arm, had a 1-point improvement (using the IGA scoring system) at a higher rate than that of patients in the placebo arm. This is another clear indication of the drug’s efficacy. Increases in Prurisol’s therapeutic response, upon evaluating patients at Day 56 (Week 8) and Day 84 (Week 12) of treatment, also were apparent in the Prurisol 200mg arm, suggesting an improving response over time.

Cellceutix is extremely proud of the Phase 2 Prurisol results. Simply put, the drug’s efficacy compares favorably with many current and various types of treatments for psoriasis (see the study linked to below), including apremilast or Otezla®, which is the leading oral FDA approved anti-psoriasis drug. It is interesting to do a side-by-side comparison between the two based on publicly available literature, and it could be argued that Prurisol performs on par with, if not better than, Otezla® at the identical stage of development

My opinion on favorable factors: oral and earlier impact are 2 big selling points.